Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: A randomized, controlled trial in children primed according to a 2+1 schedule in infancy

Human Vaccines and Immunotherapeutics

Volumn 8, Issue 3, 2012, Pages 345-352

  Ferrera, Giuseppe ^a   Cuccia, Mario ^b   Mereu, Gabriele ^c   Icardi, Giancarlo ^d   Bona, Gianni ^e   Esposito, Susanna ^f   Marchetti, Federico ^g   Messier, Marc ^g   Kuriyakose, Sherine ^g   Hardt, Karin ^g  

^a Azienda Sanitaria Provinciale di Ragusa   (Italy)

^b Settore Igiene Pubblica   (Italy)

^c Servizio di Igiene Pubblica   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g GSK   (Italy)

Author keywords

Diphtheria tetanus acellular pertussis inactivated poliovirus vaccine; Italy; MMRV; Pre school

Indexed keywords

CHICKENPOX MEASLES MUMPS RUBELLA VACCINE; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; PRIORIX TETRA; TETANUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

ANTIBODY TITER; ARTICLE; CHICKENPOX; CHILD; CHILD CARE; CONTROLLED STUDY; DIPHTHERIA; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MEASLES; MULTICENTER STUDY; MUMPS; OUTCOME ASSESSMENT; PAIN; PERTUSSIS; PHASE 3 CLINICAL TRIAL; POLIOMYELITIS; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; RUBELLA; SINGLE DRUG DOSE; SKIN REDNESS; SWELLING; TETANUS; VACCINATION; VACCINATION REACTION;

EID: 84860379057     PISSN: None     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.8.3.18650     Document Type: Article

References (27)

1. Celentano LP, Massari M, Paramatti D, Salmaso S, Tozzi AE & EUVAC-NET Group. Resurgence of pertussis in Europe. Pediatr Infect Dis J 2005; 24:761-5; PMID:16148840; http://dx.doi.org/10.1097/01.inf.0000177282.53500.77
2. Vergara R, Tregnaghi M, Ussher J, Navarro S, Rüttimann R, Potin M, et al. Reduced-antigen-content-diphtheria-tetanus-acellular-pertussis and inactivated polio vaccine as a booster for adolescents 10 to 14 years of age. Eur J Pediatr 2005; 164:377-82; PMID:15782295; http://dx.doi.org/10.1007/s00431- 005-1650-y
3. Rota MC, D'Ancona F, Massari M, Mandolini D, Giammanco A, Carbonari P, et al. How increased pertussis vaccination coverage is changing the epidemiology of pertussis in Italy. Vaccine 2005; 23:5299-305; PMID:16112254; http://dx.doi.org/10.1016/j.vaccine.2005.07.061
4. http://www.salute.gov.it/imgs/C_17_pagineAree_811- listaFile_itemName_12_file.pdf
5. Hewlett EL, Edwards KM. Clinical practice. Pertussis - not just for kids. N Engl J Med 2005; 352:1215-22; PMID:15788498; http://dx.doi.org/10.1056/ NEJMcp041025
6. Roehr B. Eight babies die in Californian whooping cough outbreak. BMJ 2010; 341:c4627; PMID:20736256; http://dx.doi.org/10.1136/bmj.c4627
7. Barret AS, Ryan A, Breslin A, Cullen L, Murray A, Grogan J, et al. Pertussis outbreak in northwest Ireland, January-June 2010. Euro Surveill. 2010;15(35):pii=19654. Available online: http://www.eurosurveillance. org/ViewArticle.aspx?ArticleId=19654.
8. Roper K & Surveillance Branch, Office of Health Protection. Outbreak of pertussis, 1 January to 31 March 2009. Commun Dis Intell 2009; 33:36-7; PMID:19618768
9. Kjeldsen K, Simonsen O, Heron I. Immunity against diphtheria 25-30 years after primary vaccination in childhood. Lancet 1985; 1:900-2; PMID:2858748; http://dx.doi.org/10.1016/S0140-6736(85)91675-7
10. Chiarini A, Giammanco A, Stroffolini T, De Mattia D, Masia MD, Sarzana A, et al. Immunity to diphtheria in the 3-19 year age group in Italy. Vaccine 1991; 9:837-9; PMID:1759506; http://dx.doi.org/10.1016/0264-410X(91)90222-R
11. Olin P, Gustafsson L, Barreto L, Hessel L, Mast TC, Rie AV, et al. Declining pertussis incidence in Sweden following the introduction of acellular pertussis vaccine. Vaccine 2003; 21:2015-21; PMID:12706691; http://dx.doi.org/ 10.1016/S0264-410X(02)00777-6
12. Sänger R, Behre U, Krause K-H, Loch H-P, Soemantri P, Herrmann D, et al. Booster vaccination and 1-year follow-up of 4-8-year-old children with a reduced-antigen- content dTpa-IPV vaccine. Eur J Pediatr 2007; 166:1229-36; PMID:17235521; http://dx.doi.org/10.1007/s00431-006-0403-x
13. Meyer CU, Habermehl P, Knuf M, Hoet B, Wolter J, Zepp F. Immunogenicity and reactogenicity of acellular pertussis booster vaccines in children: standard pediatric versus a reduced-antigen content formulation. Hum Vaccin 2008; 4:203-9; PMID:18382142; http://dx.doi.org/10.4161/hv.4.3.5290
14. Cheuvart B, Burgess M, Zepp F, Mertsola J, Wolter J, Schuerman L. Anti-diphtheria antibody seroprotection rates are similar 10 years after vaccination with dTpa or DTPa using a mathematical model. Vaccine 2004; 23:336-42; PMID:15530678; http://dx.doi.org/10.1016/j.vaccine.2004.06.012
15. Rennels MB. Extensive swelling reactions occurring after booster doses of diphtheria-tetanus-acellular pertussis vaccines. Semin Pediatr Infect Dis 2003; 14:196-8; PMID:12913831; http://dx.doi.org/10.1016/S1045-1870(03)00033-5
16. Knuf M, Vetter V, Celzo F, Ramakrishnan G, Van Der Meeren O, Jacquet JM. Repeated administration of a reduced-antigen-content diphtheria-tetanus- acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV). Hum Vaccin 2010; 6:554-61; PMID:20448468; http://dx.doi.org/10.4161/hv.6.7.11760
17. Ciofi degli Atti ML, Salmaso S, Cotter B, Gallo G, Alfarone G, Pinto A, et al. Reactogenicity and immunogenicity of adult versus pediatric diphtheria and tetanus booster dose at 6 years of age. Vaccine 2002; 20:74-9; http://dx.doi.org/10.1016/S0264-410X(01)00316-4
18. McIntyre PB, Burgess MA, Egan A, Schuerman L, Hoet B. Booster vaccination of adults with reduced-antigen-content diphtheria, Tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine 2009; 27:1062-6; PMID:19095033; http://dx.doi.org/10.1016/j.vaccine.2008.11.102
19. Mertsola J, Van Der Meeren O, He Q, Linko-Parvinen A, Ramakrishnan G, Mannermaa L, et al. Decennial administration of a reduced antigen content diphtheria and tetanus toxoids and acellular pertussis vaccine in young adults. Clin Infect Dis 2010; 51:656-62; PMID:20704493; http://dx.doi.org/10.1086/655825
20. http://www.societaitalianaigiene.org/cms/images/docs/calendariovaccinale/ infanzia.pdf
21. Gajdos V, Soubeyrand B, Vidor E, Richard P, Boyer J, Sadorge C, et al. Immunogenicity and safety of combined adsorbed low-dose diphtheria, tetanus and inactivated poliovirus vaccine (REVAXIS) versus combined diphtheria, tetanus and inactivated poliovirus vaccine (DT Polio) given as a booster dose at 6 years of age. Hum Vaccin 2011; 7:549-56; PMID:21441781; http://dx.doi.org/10.4161/hv.7. 5.14982
22. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-16; PMID:9796042; http://dx.doi.org/10.1016/S0264-410X(98)00227-8
23. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand 1983; 11:137-44; PMID:6345548; http://dx.doi.org/10.1016/S0092-1157(83) 80038-9
24. Granström M, Thorén M, Blennow M, Tiru M, Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol 1987; 6:18-21; PMID:2883004; http://dx.doi.org/10.1007/BF02097184
25. Karpinski KF, Hayward S, Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods 1987; 103:189-94; PMID:3668258; http://dx.doi.org/10.1016/0022-1759(87)90289-4
26. Sato Y, Sato H, Izumiya K, et al. Role of antibody to filamentous hemagglutinin and to leukocytosis promoting factor-hemagglutinin in immunity to pertussis. In: Robbins J B, Hill J C, Sardoff J C ed. Seminars in Infectious Disease: Bacterial Vaccines. New-York: Thierne-Stratton, Inc. 1982; 380-5.
27. World Health Organization. Guidelines for WHO/EP/Collaborative Studies on Poliomyelitis. Standard Procedure for Determining immunity to Poliovirus using the Microneutralization Test. WHO/EPI/GEN/93.9. World Health Organization, Geneva. 1993.